Abstract Analysis of the IMvigor 210 trials involving patients with platinum-refractory or
cisplatin-ineligible urothelial carcinoma who were treated with the PD-L1 inhibitor …

The progression of urothelial bladder cancer (UC) is a complicated multi-step process. We
perform a comprehensive multi-omics analysis of 448 samples from 190 UC patients …

Molecular stratification can improve the management of advanced cancers, but requires
relevant tumor samples. Metastatic urothelial carcinoma (mUC) is poised to benefit given a …

Immune checkpoint inhibitor (ICI) treatment has been used to treat advanced urothelial
cancer. Molecular markers might improve risk stratification and prediction of ICI benefit for …

Abstract Background and Objective Genomic alterations in fibroblast growth factor receptor
(FGFR) genes have been linked to a reduced response to immune checkpoint inhibitors …

PURPOSE Immune checkpoint blockade (ICB) therapy has significantly improved clinical
outcomes in bladder cancer. Identification of correlates of benefit is critical to select …

Effective management of advanced urothelial bladder cancer is challenging. New
discoveries that improve our understanding of molecular bladder cancer subtypes have …

Background Mutations of DNA repair genes, eg ATM/RB1, are frequently found in urothelial
cancer (UC) and have been associated with better response to cisplatin-based …

Introduction: Knowledge of the molecular subtypes of bladder cancer enables powerful
generalizations involving the distinctive biology and pathways driving different disease …

Bladder cancer is the fourth most common cancer in men and the ninth most common in
women in the Western world. The management of bladder carcinoma requires a …